Arrowhead presents expanded patient profile data for cholesterol asset
Arrowhead Pharmaceuticals (NASDAQ:ARWR) unveiled new clinical data expanding the medical profile of plozasiran, its approved RNA interference (RNAi) therapeutic, demonstrating that the drug can be administered to patients suffering from moderate-to-severe renal impairment or moderate hepatic impairment without necessitating a reduction in dose.
The Pasadena, California-based biotechnology firm presented the findings across two oral sessions at the 94th European Atherosclerosis Society (EAS) Congress in Athens, Greece.
The updates aim to broaden the addressable patient population for the drug, which functions by curbing the hepatic production of apolipoprotein C-III (APOC3) to dramatically lower fasting blood triglycerides.
Plozasiran is already commercially approved in the United States, China, Australia, and Canada as a dietary adjunct for adults with familial chylomicronemia syndrome (FCS)—a rare genetic metabolic disorder—and is under late-stage clinical evaluation for severe hypertriglyceridemia (sHTG).
Because patients suffering from these extreme lipid elevations frequently present with secondary organ comorbidities like hepatic steatosis (fatty liver) or renal decline, defining the drug's safety boundaries in these sub-populations remains critical for widespread clinical adoption.
The company’s pharmacokinetics and pharmacodynamics study evaluated a single 25 mg dose of plozasiran.
Investigators reported that despite tracking modest increases in systemic drug exposure among compromised individuals, the actual down-regulation of APOC3 and corresponding triglyceride reductions were virtually identical between healthy control groups and those with moderate-to-severe renal or moderate hepatic impairment.
The compound was flagged as generally safe and well-tolerated, showing no novel safety signal variations.
In a separate presentation, Arrowhead highlighted an unusual patient case study tracing a female FCS patient who discontinued plozasiran therapy prior to conception.
The tracking data indicated that preconception exposure to the RNAi drug was associated with a sustained depression of fasting triglyceride levels through the full term of her pregnancy.
The data marks the second successful pregnancy case study pulled from the company’s broader PALISADE clinical program.
While management emphasized that extensive clinical data is still required to safely establish the baseline parameters of APOC3-targeted interventions during pregnancy, they noted the prolonged therapeutic effects mirror the extended drug durability metrics documented in prior trials.